CO2023010721A2 - Anticuerpos contra la calicreína plasmática y usos de estos - Google Patents
Anticuerpos contra la calicreína plasmática y usos de estosInfo
- Publication number
- CO2023010721A2 CO2023010721A2 CONC2023/0010721A CO2023010721A CO2023010721A2 CO 2023010721 A2 CO2023010721 A2 CO 2023010721A2 CO 2023010721 A CO2023010721 A CO 2023010721A CO 2023010721 A2 CO2023010721 A2 CO 2023010721A2
- Authority
- CO
- Colombia
- Prior art keywords
- plasma kallikrein
- antibodies against
- antibodies
- against plasma
- antigen
- Prior art date
Links
- 102000003827 Plasma Kallikrein Human genes 0.000 title abstract 2
- 108090000113 Plasma Kallikrein Proteins 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 101800004538 Bradykinin Proteins 0.000 abstract 1
- 206010018713 Gravitational oedema Diseases 0.000 abstract 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 1
- 206010019860 Hereditary angioedema Diseases 0.000 abstract 1
- 102100035792 Kininogen-1 Human genes 0.000 abstract 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
En el presente documento se proporcionan anticuerpos y composiciones que contienen tales anticuerpos o fragmentos de unión al antígeno de estos que se unen a la calicreína plasmática. El presente documento también proporciona métodos para producir y usar tales anticuerpos o fragmentos de unión al antígeno de estos, como en el tratamiento de angioedema hereditario o edema dependiente de bradicinina.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142748P | 2021-01-28 | 2021-01-28 | |
| US202163159323P | 2021-03-10 | 2021-03-10 | |
| US202163220194P | 2021-07-09 | 2021-07-09 | |
| US202163262838P | 2021-10-21 | 2021-10-21 | |
| PCT/US2022/014242 WO2022165130A1 (en) | 2021-01-28 | 2022-01-28 | Plasma kallikrein antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023010721A2 true CO2023010721A2 (es) | 2023-09-08 |
Family
ID=82653858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0010721A CO2023010721A2 (es) | 2021-01-28 | 2023-08-16 | Anticuerpos contra la calicreína plasmática y usos de estos |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4284839A1 (es) |
| JP (1) | JP2024509497A (es) |
| KR (1) | KR20230137410A (es) |
| AU (1) | AU2022214914A1 (es) |
| CA (1) | CA3208312A1 (es) |
| CO (1) | CO2023010721A2 (es) |
| IL (1) | IL304587A (es) |
| MX (1) | MX2023008926A (es) |
| TW (1) | TW202246350A (es) |
| WO (1) | WO2022165130A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10428158B2 (en) * | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
-
2022
- 2022-01-28 JP JP2023541513A patent/JP2024509497A/ja active Pending
- 2022-01-28 MX MX2023008926A patent/MX2023008926A/es unknown
- 2022-01-28 CA CA3208312A patent/CA3208312A1/en active Pending
- 2022-01-28 AU AU2022214914A patent/AU2022214914A1/en active Pending
- 2022-01-28 WO PCT/US2022/014242 patent/WO2022165130A1/en active Application Filing
- 2022-01-28 KR KR1020237029135A patent/KR20230137410A/ko unknown
- 2022-01-28 EP EP22746663.8A patent/EP4284839A1/en active Pending
- 2022-01-28 TW TW111104148A patent/TW202246350A/zh unknown
-
2023
- 2023-07-19 IL IL304587A patent/IL304587A/en unknown
- 2023-08-16 CO CONC2023/0010721A patent/CO2023010721A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL304587A (en) | 2023-09-01 |
| EP4284839A1 (en) | 2023-12-06 |
| CA3208312A1 (en) | 2022-08-04 |
| WO2022165130A1 (en) | 2022-08-04 |
| TW202246350A (zh) | 2022-12-01 |
| JP2024509497A (ja) | 2024-03-04 |
| MX2023008926A (es) | 2023-10-23 |
| KR20230137410A (ko) | 2023-10-04 |
| AU2022214914A1 (en) | 2023-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020014575A2 (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos | |
| CL2019002566A1 (es) | Anticuerpos anti-phf-tau y usos de estos. | |
| CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
| CO2017001317A2 (es) | Composición farmacéutica con anticuerpos anti cd40 y kit | |
| CO2017007123A2 (es) | Anticuerpos biespecíficos contra calicreína y factor xii del plasma | |
| EA201991071A1 (ru) | Композиции и способы для лечения ezh2-опосредованного рака | |
| ECSP12012309A (es) | Anticuerpos hacia gdf8 humano | |
| CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
| ECSP19029758A (es) | Anticuerpos anti-il-33 y usos de los mismos | |
| BR112021023026A2 (pt) | Moléculas de ligação biespecíficas anti-ror1/anti-cd3 | |
| CR20180529A (es) | Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada | |
| CL2019001749A1 (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
| ECSP22078815A (es) | Anticuerpos anti-phf-tau y usos de estos | |
| CO2023006684A2 (es) | Anticuerpos contra sars-cov-2 y usos de los mismos | |
| BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
| PE20212132A1 (es) | Agentes de union a c3 y metodos para su uso | |
| AR119507A1 (es) | Anticuerpos triespecíficos anti-pd-1 / lag3 / tigit y anticuerpos biespecíficos anti-pd-1 / lag3 | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| UY39699A (es) | Anticuerpos anti-tau y usos de estos | |
| WO2018150276A3 (en) | The combination of cotinine plus antioxidant for treatment resistant depression and other neuropathological conditions | |
| CO2023002034A2 (es) | Moléculas de unión a antígeno multi-específicas contra el vih y métodos de uso | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| ECSP21087921A (es) | Materiales y métodos para modular la inmunidad mediada por células t | |
| CO2023010721A2 (es) | Anticuerpos contra la calicreína plasmática y usos de estos | |
| CL2023002213A1 (es) | Anticuerpos contra la calicreína plasmática y usos de estos. |